Section Arrow
Quote
PVLA.NASDAQ
- Palvella Therapeutics Inc
Quotes are at least 15-min delayed:2026/04/05 18:59 EDT
Regular Hours
Last
 123.46
+3.08 (+2.56%)
Day High 
127.31 
Prev. Close
120.38 
1-M High
143.76 
Volume 
335.11K 
Bid
115.5
Ask
164.43
Day Low
115.34 
Open
120.19 
1-M Low
108.63 
Market Cap 
1.68B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 116.57 
20-SMA 123.67 
50-SMA 106.05 
52-W High 151.18 
52-W Low 18.225 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.71/-4.68
Enterprise Value
1.68B
Balance Sheet
Book Value Per Share
1.96
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
COCPCocrystal Pharma1.51+0.49+48.04%-- 
BDRXBiodexa Pharmaceuticals plc0.8733+0.2593+42.23%-- 
IOBTIO Biotech0.0323-0.0114-26.09%-- 
GERNGeron Corp1.66------ 
ELABPmgc Holdings Inc5.72-8.28-59.14%0PE
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.